Command Palette

Search for a command to run...

BAFNAPH

159.22+0.00%
Market Cap
₹376.66 Cr
Stock P/E
-15.23
ROCE
-2.99%
ROE
-25.42%
Book Value
₹0.00

Financials

YoY Net Sales
EPS Growth
Operating Margin

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings
Distribution
Promoter
Institution
Public
Others

From Last Concall

No Concall Summary

Conference call summary is not available for this stock.

Peers Summary

Sector Laggard

Bafna Pharmaceuticals Ltd. significantly lags behind its peers in key financial metrics, including revenue growth, profitability, and efficiency. Its negative ROE and high PE ratio indicate financial distress, making it a risky investment compared to stronger competitors in the pharmaceuticals sector.

Key Points
  • Bafna Pharmaceuticals has the lowest revenue growth, EPS, ROA, ROE, and EBITDA margin among peers.
  • Sun Pharmaceutical Industries and Cipla Ltd. stand out as strong performers with robust growth and profitability metrics.
  • Bafna Pharmaceuticals has a concerning debt-equity ratio which indicates financial instability.
Top Performers
Cipla Ltd.

Leading in profitability with a PE of 23.73, ROE of 16.63%, and solid revenue growth of 13.28% YoY.

Sun Pharmaceutical Industries Ltd.

Strong revenue growth (8.42% YoY) and profitability metrics (ROE of 16.13%), though it has a high PE of 87.59.

Dr. Reddy's Laboratories Ltd.

Strong overall metrics with a low PE (15.50) and high profitability (ROE of 21.76%).

Leveling the playing field in markets.

© 2025 EQHQ Technologies Pvt Ltd

"Information provided is for educational purposes only and not financial advice.